14.02.2024 - Results from 112 patients with DMD who completed the study confirm maintenance of efficacy and benefits in safety and tolerability of treatment with vamorolone over 48 weeks AGAMREE has shown safety benefits in patients switching from standard of . Seite 1
18.12.2023 - European Commission (EC) grants marketing authorization for AGAMREE for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and olderAGAMREE is the only approved medication in the European Union (EU) for treating DMD, and the . Seite 1